Jana Partners Takes Positions in Adobe, Apple, Anthem, AutoDesk, Others
Barry Rosenstein

Barry Rosenstein's Jana Partners, the activist fund that drove Whole Foods to sell itself to Amazon.com (AMZN) last year, has a number of interesting new big investments in the first quarter of this year, any of which could become activist targets in the coming months.

These include: Adobe Systems Inc. (ADBE) , ADT Inc. (ADT) , Agilent Technologies Inc. (A) , Allergan Plc (AGN) , Anthem Inc. (ANTM) , Apple Inc. (AAPL) , Boston Scientific (BSX) , Cigna Corp. (CI) , Discovery Communications (DISCA) and Dr. Pepper Snapple Group Inc. (DPS) .

The new investments were revealed in Jana Partners' first-quarter 2018 13F securities filing, which is based on positions the activist fund held as of March 30.

According to the securities filing, Jana Partners held $51.7 million worth of shares in Adobe Systems, $2.5 million in ADT, $68 million in Agilent Technologies.

Editor's note: The full version of this article was published by The Deal, a sister publication of TheStreet that offers sophisticated insight and analysis on all types of deals. Click here for a free trial.

There's still time get your ticket to join host Jim Cramer and keynotes Paul Singer, Nelson Peltz, Jeff Gennette and Steve Mollenkopf at the Corporate Governance conference on June 7, 2018 in NYC. Gain insight on methods for managing companies to maximize shareholder value. Registration ends on June 4 so get your ticket today. Special pricing available for The Deal's readers; for more details contact your account manager.

More from Markets

Nvidia Shares Fall After Beating Earnings but Issuing Light Guidance

Nvidia Shares Fall After Beating Earnings but Issuing Light Guidance

Rewind: Jim Cramer on the Stock Market Rebound, Walmart, Amazon and JCPenney

Rewind: Jim Cramer on the Stock Market Rebound, Walmart, Amazon and JCPenney

Is Nvidia Still Tech's Most Explosive Stock? A Bull and Bear Debate

Is Nvidia Still Tech's Most Explosive Stock? A Bull and Bear Debate

Teva Notches Win With FDA Approval of Generic EpiPen

Teva Notches Win With FDA Approval of Generic EpiPen

Dow Jumps Nearly 300 Points as U.S. and China to Resume Trade Talks

Dow Jumps Nearly 300 Points as U.S. and China to Resume Trade Talks